| [1] |
中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识[J]. 中华临床感染病杂志, 2017, 10(2):81-90.
|
|
AIDS Group, Infectious Diseases Branch, Chinese Medical Association; AIDS Group, Tropical Diseases and Parasitics Branch, Chinese Medical Association. Expert consensus on diagnosis and treatment of HIV infection combined with Mycobacterium tuberculosis infection[J]. Chin J Clin Infect Dis, 2017, 10(2):81-90.
|
| [2] |
中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J]. 中华传染病杂志, 2022, 40(1):6-19.
|
|
HIV Tuberculosis Committee of China Association for STD and AIDS Prevention and Control. Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome[J]. Chin J Infect Dis, 2022, 40(1):6-19.
|
| [3] |
中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J]. 新发传染病电子杂志, 2022, 7(1):73-87.
|
|
HIV Tuberculosis Committee of China Association for STD and AIDS Prevention and Control. Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome[J]. Electron J Emerg Infect Dis, 2022, 7(1):73-87.
|
| [4] |
World Health Organization. HIV/AIDS[EB/OL]. 2021-11-30[2022-03-20]. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
|
| [5] |
World Health Organization. Global tuberculosis report 2021[M/OL]. Geneva: World Health Organization. 2021-10-14[2022-03-20]. https://www.who.int/publications/i/item/9789240037021.
|
| [6] |
Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection[J]. Nat Rev Microbiol, 2018, 16(2):80-90.
doi: 10.1038/nrmicro.2017.128
URL
|
| [7] |
吴雪韵, 沈银忠. 人类免疫缺陷病毒与结核分枝杆菌合并感染发病机制的研究进展[J]. 内科理论与实践, 2019, 14(4):253-258.
|
|
Wu XY, Shen YZ. The pathogenesis of human immunodeficiency virus and Mycobacterium tuberculosis co-infection: research progress and literature review[J]. J Intern Med Concepts & Pract, 2019, 14(4):253-258.
|
| [8] |
郭静, 沈银忠. HIV感染/AIDS合并结核病的临床及免疫学特点研究进展[J]. 诊断学理论与实践, 2021, 20(4):401-406.
|
|
Guo J, Shen YZ. Progress in study on clinical and immunological features of HIV/AIDS complicated with tuberculosis[J]. J Diagn Concepts & Pract, 2021, 20(4):401-406.
|
| [9] |
WHO operational handbook on tuberculosis (Module 1: prevention): tuberculosis preventive treatment[M/OL]. Geneva, World Health Organization. 2020[2021-03-20]. https://apps.who.int/iris/bitstream/handle/10665/331525/9789240002906-eng.pdf.
|
| [10] |
Luo B, Sun J, Cai R, et al. Spectrum of opportunistic infections and risk factors for in-hospital mortality of admitted AIDS patients in Shanghai[J]. Medicine (Baltimore), 2016, 95(21):e3802.
doi: 10.1097/MD.0000000000003802
URL
|
| [11] |
Qi T, Zhang R, Shen Y, et al. Etiology and clinical features of 229 cases of bloodstream infection among Chinese HIV/AIDS patients: a retrospective cross-sectional study[J]. Eur J Clin Microbiol Infect Dis, 2016, 35(11):1767-1770.
doi: 10.1007/s10096-016-2724-7
URL
|
| [12] |
Qi TK, Chen J, Zhang RF, et al. A retrospective cohort study of early mortality among patients with HIV/TB co-infection in Shanghai municipality[J]. HIV Med, 2020, 21(11):739-746.
doi: 10.1111/hiv.13025
pmid: 33369033
|
| [13] |
Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis[J]. N Engl J Med, 2019, 380(11):1001-1011.
doi: 10.1056/NEJMoa1806808
URL
|
| [14] |
Agizew T, Basotli J, Alexander H, et al. Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay[J]. PLoS One, 2017, 12(12):e0189981.
|
| [15] |
Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis[J]. N Engl J Med, 2021, 384(18):1705-1718.
doi: 10.1056/NEJMoa2033400
URL
|
| [16] |
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach[M/OL]. Geneva: World Health Organization. 2021-07-16 [2022-03-21]. https://www.who.int/publications/i/item/9789240031593.
|
| [17] |
WHO operational handbook on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment[M/OL]. Geneva: World Health Organization, 2020[2022-03-21]. https://www.who.int/publications-detail-redirect/9789240006997.
|
| [18] |
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(10):733-749.
|
|
Chinese Society of Tuberculosis of Chinese Medical Association. Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment[J]. Chin J Tuberc & Respir Dis, 2019, 42(10):733-749.
|
| [19] |
中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华内科杂志, 2021, 60(12):1106-1128.
|
|
AIDS Hepatitis C Group, Infectious Diseases Branch, Chinese Medical Association, China Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)[J]. Chin J Intern Med, 2021, 60(12):1106-1128.
|
| [20] |
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services[EB/OL]. 2022-01-20[2022-03-21]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.
|
| [21] |
European AIDS Clinical Society. EACS Guidelines (Version 11.0)[EB/OL]. 2021-10[2022-03-21]. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.
|
| [22] |
Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized Trial[J]. Clin Infect Dis, 2020, 70(4):549-556.
doi: 10.1093/cid/ciz256
pmid: 30918967
|
| [23] |
de Castro N, Marcy O, Chazallon C, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial[J]. Lancet Infect Dis, 2021, 21(6):813-822.
doi: 10.1016/S1473-3099(20)30869-0
URL
|
| [24] |
Kendall MA, Lalloo U, Fletcher CV, et al. Safety and Pharmacokinetics of double-dose lopinavir/ritonavir + rifampin versus lopinavir/ritonavir + daily rifabutin for treatment of human immunodeficiency virus-tuberculosis coinfection[J]. Clin Infect Dis, 2021, 73(4):706-715.
doi: 10.1093/cid/ciab097
URL
|
| [25] |
Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[EB/OL]. 2022-02-17[2022-03-21]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf.
|
